Skip to main content

Table 3 Costs (SEK) of health care and treatments (including cardiovascular costs) before and after starting the insulin treatment

From: Total costs of basal or premixed insulin treatment in 5077 insulin-naïve type 2 diabetes patients: register-based observational study in clinical practice

  Pre-index Post-index Increment Net cost effect
  Health care Treatment Health care Treatment Health care Treatment
Treatment Mean/Median Mean/Median Mean/Median Mean/Median Mean/Median Mean/Median Mean/Median
NPH 24,791/3,681 3,449/2,398 19,390/3,681 9,279/7,879 −5,401/0 5,831/4,659 430/4,659
IG 25,197/3,681 3,920/2,679 23,539/3,681 11,967/10,670 −1,658/0 8,047/6,569 6,389/6,569
ID 17,981/2,613 3,815/2,194 13,070/2,955 13,143/11,306 −4,912/0 9,328/7,808 4,416/7,808
PM 36,724/6,366 3,183/2,259 26,388/4,262 9,744/8,800 −10,336/-773 6,560/6,010 −3,776/5,237
p-values <0.0001 <0.0012 <0.0001 <0.0001 0.0022 <0.0001  
  1. NPH Neutral protamine Hagedorn, IG insulin glargine, ID insulin determir, PM premixed insulin, SD standard deviation. The approximate value of 100 SEK is currently 12 US dollars (August 2015)